Nuvation Bio Inc. — Q1 2023 Form 10-Q Summary
Business context and reporting period
Clinical-stage oncology biopharmaceutical company; this unaudited filing covers the three months ended March 31, 2023, with comparisons to Q1 2022. The company had no commercially approved products and reported no product, collaboration, or other revenue.
NUV-868 is in Phase 1 monotherapy and Phase 1b combination dose-escalation studies, with enrollment ongoing. The company expects to submit an IND for its first nominated drug-drug conjugate (DDC) candidate by year-end 2023.
Financial results and liquidity
| Metric | Q1 2023 | Q1 2022 / comparison |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $18.8 million | $20.7 million; down $1.9 million |
| General and administrative expense | $7.7 million | $7.5 million; up $0.3 million |
| Total operating expenses / operating loss | $26.5 million | $28.2 million; operating loss narrowed $1.7 million |
| Other income, net | $4.8 million | $6.9 million |
| Net loss | $21.7 million | $21.3 million |
| Net loss per share, basic and diluted | $0.10 | $0.10 |
| Operating cash used | $19.3 million | $24.9 million |
At March 31, 2023, cash and cash equivalents were $30.1 million and marketable securities were $616.5 million, for combined cash, cash equivalents, and marketable securities of $646.6 million. Total current assets were $652.6 million and current liabilities $12.6 million. The company reported no funded debt; liabilities included $4.0 million of operating lease obligations and a $0.7 million warrant liability. Accumulated deficit was $288.7 million.
Cash and cash equivalents fell by $71.0 million during the quarter, principally reflecting $52.0 million of net investing cash outflow as the company purchased and sold marketable securities. Stock-based compensation was $4.8 million. Operating margins are not meaningful because there was no revenue.
Changes versus the prior comparable period
- R&D expense declined 9%, attributed mainly to $1.3 million lower personnel costs following a headcount reduction and $0.6 million lower third-party research and manufacturing costs, including costs related to termination of the NUV-422 program.
- G&A expense increased modestly; higher personnel costs, including stock compensation and benefits, were partly offset by lower insurance and professional fees.
- Net loss increased slightly despite lower operating expenses. Other income fell by $2.1 million, chiefly because the favorable change in warrant fair value was $6.2 million smaller than in Q1 2022; higher investment interest income partly offset this.
- Comprehensive loss improved to $19.1 million from $26.3 million, including a $2.6 million unrealized gain on available-for-sale securities versus a $5.0 million unrealized loss a year earlier.
Outlook, risks, and contingencies
Management expects continuing operating losses and negative operating cash flows. It believes existing cash, cash equivalents, and marketable securities will fund commitments for at least 12 months after issuance of the financial statements. Future spending and financing needs depend on development progress and other factors; additional capital may be needed, and financing could dilute shareholders or require granting rights to programs or technology.
Key risks include clinical and regulatory uncertainty, patient enrollment and trial delays, reliance on third-party research, clinical-trial and manufacturing providers, competition, intellectual-property challenges, and the unproven DDC platform. The filing notes that three of five programs pursued as of February 2022 had been discontinued or deprioritized; NUV-422 development was discontinued in August 2022 following a uveitis safety signal.
Marketable securities had $3.4 million of unrealized losses at quarter-end, primarily attributed to interest-rate changes. Management stated it did not intend, and did not expect to be required, to sell the securities before recovery of amortized cost; it recorded no expected credit-loss allowance. The company disclosed $0.6 million of standby letters of credit securing office leases and no pending significant legal proceedings believed likely to materially affect its financial position. Management assessed disclosure controls as effective at March 31, 2023.
Important facts for investors to verify
- Whether the stated cash runway remains valid as clinical-development spending and program priorities evolve.
- Enrollment, safety, and results from both NUV-868 trials, and progress toward the anticipated year-end 2023 DDC IND submission.
- Further details and financial implications of the discontinued or deprioritized programs, including NUV-422.
- Portfolio composition, maturities, and interest-rate exposure of marketable securities, including the unrealized losses.
- Potential share dilution from 30.9 million outstanding options and the governance implications of the dual-class share structure.